View in EDS PDF Full Text

Parvovirus B19 infection presenting as polyarthritis: a nationwide clinical and epidemiological study.

Saved in:
Bibliographic Details
Title: Parvovirus B19 infection presenting as polyarthritis: a nationwide clinical and epidemiological study.
Authors: Rodrigues, S. D.1,2 saradiasrodrigues11@gmail.com, Santos, M. E.1,2, Moniz, A. C.1,2, Melim, D.1,3, Tremoceiro, J.1, Leão, A.4, Melo, A. T.5, Mendonça, B.4, Ferreira, C.6, Albuquerque, F.7, Lourenço, M. H.8, Pacheco, M. J.9, Natal, M.10, Branco, J. C.1,2, Lopes, C.1,2
Source: ARP Rheumatology. Apr-Jun2026, Vol. 5 Issue 2, p123-128. 6p.
Subjects: Parvovirus B19, Arthritis, Autoimmunity, Nonsteroidal anti-inflammatory agents, Infectious arthritis, Antirheumatic agents, Corticosteroids, Immunoglobulin M
Abstract: Viral arthritis accounts for approximately 1% of acute arthritis cases and may be caused by several viruses, particularly parvovirus B19 (B19V). Diagnosis relies on clinical presentation, B19V immunoglobulin M (IgM) and/or immunoglobulin G (IgG) seropositivity, and the exclusion of other infectious and non-infectious etiologies. Following a European outbreak of B19V between March and May 2024, we conducted a multicenter retrospective study. The primary outcomes were the clinical and laboratory manifestations of B19V-associated arthritis; secondary outcomes included progression to chronic inflammatory disease and the need for escalation to disease-modifying antirheumatic drugs (DMARDs). A total of 28 patients (25 women and 3 men) were included, with a mean age of 44 ± 11.4 years; 16 patients (57.1%) reported epidemiological risk factors. Acute, additive, symmetrical inflammatory polyarthralgia was the predominant clinical feature (26 patients, 92.9%), while axial inflammatory pain was reported by four patients (14.3%). Laboratory evaluation revealed positivity for antinuclear antibody (ANA) in 32.1%, rheumatoid factor (RF) in 19.7%, and HLA-B27 in 7.1% of patients. Anti–double-stranded DNA (dsDNA) and anti–cyclic citrullinated peptide antibodies (ACPA) were negative in all cases. Complement consumption was observed in a minority of patients, with low C3 levels in four (14.3%) and low C4 levels in three patients (10.7%). Regarding treatment, 39.3% of patients received nonsteroidal anti-inflammatory drugs (NSAIDs), while 60.7% were treated with systemic corticosteroids (prednisolone 10–40 mg/day); one patient required intravenous methylprednisolone (125 mg). Clinical remission was achieved in 24 patients (85.7%) after a mean duration of 34 ± 47.0 days. However, four patients experienced relapse during corticosteroid tapering, suggesting potential progression to a chronic inflammatory condition. Among these, one patient achieved adequate symptom control with intermittent courses of NSAID alone, whereas the remaining three required initiation of DMARD therapy. This study provides one of the most comprehensive characterizations of B19V–associated arthritis in immunocompetent adults. Our findings emphasizes B19V infection as a significant viral mimic of early inflammatory rheumatic diseases and suggests considering it in the differential diagnosis of acute polyarthritis. Moreover, our study highlights the uncommon but notable potential of B19V infection to induce persistent inflammatory responses requiring immunosuppressive therapy. [ABSTRACT FROM AUTHOR]
Copyright of ARP Rheumatology is the property of Sociedade Portuguesa de Reumatologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 195258518
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Parvovirus B19 infection presenting as polyarthritis: a nationwide clinical and epidemiological study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Rodrigues%2C+S%2E+D%2E%22">Rodrigues, S. D.</searchLink><relatesTo>1,2</relatesTo><i> saradiasrodrigues11@gmail.com</i><br /><searchLink fieldCode="AR" term="%22Santos%2C+M%2E+E%2E%22">Santos, M. E.</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Moniz%2C+A%2E+C%2E%22">Moniz, A. C.</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Melim%2C+D%2E%22">Melim, D.</searchLink><relatesTo>1,3</relatesTo><br /><searchLink fieldCode="AR" term="%22Tremoceiro%2C+J%2E%22">Tremoceiro, J.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Leão%2C+A%2E%22">Leão, A.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Melo%2C+A%2E+T%2E%22">Melo, A. T.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Mendonça%2C+B%2E%22">Mendonça, B.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Ferreira%2C+C%2E%22">Ferreira, C.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Albuquerque%2C+F%2E%22">Albuquerque, F.</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Lourenço%2C+M%2E+H%2E%22">Lourenço, M. H.</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Pacheco%2C+M%2E+J%2E%22">Pacheco, M. J.</searchLink><relatesTo>9</relatesTo><br /><searchLink fieldCode="AR" term="%22Natal%2C+M%2E%22">Natal, M.</searchLink><relatesTo>10</relatesTo><br /><searchLink fieldCode="AR" term="%22Branco%2C+J%2E+C%2E%22">Branco, J. C.</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Lopes%2C+C%2E%22">Lopes, C.</searchLink><relatesTo>1,2</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22ARP+Rheumatology%22">ARP Rheumatology</searchLink>. Apr-Jun2026, Vol. 5 Issue 2, p123-128. 6p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Parvovirus+B19%22">Parvovirus B19</searchLink><br /><searchLink fieldCode="DE" term="%22Arthritis%22">Arthritis</searchLink><br /><searchLink fieldCode="DE" term="%22Autoimmunity%22">Autoimmunity</searchLink><br /><searchLink fieldCode="DE" term="%22Nonsteroidal+anti-inflammatory+agents%22">Nonsteroidal anti-inflammatory agents</searchLink><br /><searchLink fieldCode="DE" term="%22Infectious+arthritis%22">Infectious arthritis</searchLink><br /><searchLink fieldCode="DE" term="%22Antirheumatic+agents%22">Antirheumatic agents</searchLink><br /><searchLink fieldCode="DE" term="%22Corticosteroids%22">Corticosteroids</searchLink><br /><searchLink fieldCode="DE" term="%22Immunoglobulin+M%22">Immunoglobulin M</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Viral arthritis accounts for approximately 1% of acute arthritis cases and may be caused by several viruses, particularly parvovirus B19 (B19V). Diagnosis relies on clinical presentation, B19V immunoglobulin M (IgM) and/or immunoglobulin G (IgG) seropositivity, and the exclusion of other infectious and non-infectious etiologies. Following a European outbreak of B19V between March and May 2024, we conducted a multicenter retrospective study. The primary outcomes were the clinical and laboratory manifestations of B19V-associated arthritis; secondary outcomes included progression to chronic inflammatory disease and the need for escalation to disease-modifying antirheumatic drugs (DMARDs). A total of 28 patients (25 women and 3 men) were included, with a mean age of 44 ± 11.4 years; 16 patients (57.1%) reported epidemiological risk factors. Acute, additive, symmetrical inflammatory polyarthralgia was the predominant clinical feature (26 patients, 92.9%), while axial inflammatory pain was reported by four patients (14.3%). Laboratory evaluation revealed positivity for antinuclear antibody (ANA) in 32.1%, rheumatoid factor (RF) in 19.7%, and HLA-B27 in 7.1% of patients. Anti–double-stranded DNA (dsDNA) and anti–cyclic citrullinated peptide antibodies (ACPA) were negative in all cases. Complement consumption was observed in a minority of patients, with low C3 levels in four (14.3%) and low C4 levels in three patients (10.7%). Regarding treatment, 39.3% of patients received nonsteroidal anti-inflammatory drugs (NSAIDs), while 60.7% were treated with systemic corticosteroids (prednisolone 10–40 mg/day); one patient required intravenous methylprednisolone (125 mg). Clinical remission was achieved in 24 patients (85.7%) after a mean duration of 34 ± 47.0 days. However, four patients experienced relapse during corticosteroid tapering, suggesting potential progression to a chronic inflammatory condition. Among these, one patient achieved adequate symptom control with intermittent courses of NSAID alone, whereas the remaining three required initiation of DMARD therapy. This study provides one of the most comprehensive characterizations of B19V–associated arthritis in immunocompetent adults. Our findings emphasizes B19V infection as a significant viral mimic of early inflammatory rheumatic diseases and suggests considering it in the differential diagnosis of acute polyarthritis. Moreover, our study highlights the uncommon but notable potential of B19V infection to induce persistent inflammatory responses requiring immunosuppressive therapy. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of ARP Rheumatology is the property of Sociedade Portuguesa de Reumatologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=195258518
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.63032/LIJG4472
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 6
        StartPage: 123
    Subjects:
      – SubjectFull: Parvovirus B19
        Type: general
      – SubjectFull: Arthritis
        Type: general
      – SubjectFull: Autoimmunity
        Type: general
      – SubjectFull: Nonsteroidal anti-inflammatory agents
        Type: general
      – SubjectFull: Infectious arthritis
        Type: general
      – SubjectFull: Antirheumatic agents
        Type: general
      – SubjectFull: Corticosteroids
        Type: general
      – SubjectFull: Immunoglobulin M
        Type: general
    Titles:
      – TitleFull: Parvovirus B19 infection presenting as polyarthritis: a nationwide clinical and epidemiological study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rodrigues, S. D.
      – PersonEntity:
          Name:
            NameFull: Santos, M. E.
      – PersonEntity:
          Name:
            NameFull: Moniz, A. C.
      – PersonEntity:
          Name:
            NameFull: Melim, D.
      – PersonEntity:
          Name:
            NameFull: Tremoceiro, J.
      – PersonEntity:
          Name:
            NameFull: Leão, A.
      – PersonEntity:
          Name:
            NameFull: Melo, A. T.
      – PersonEntity:
          Name:
            NameFull: Mendonça, B.
      – PersonEntity:
          Name:
            NameFull: Ferreira, C.
      – PersonEntity:
          Name:
            NameFull: Albuquerque, F.
      – PersonEntity:
          Name:
            NameFull: Lourenço, M. H.
      – PersonEntity:
          Name:
            NameFull: Pacheco, M. J.
      – PersonEntity:
          Name:
            NameFull: Natal, M.
      – PersonEntity:
          Name:
            NameFull: Branco, J. C.
      – PersonEntity:
          Name:
            NameFull: Lopes, C.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: Apr-Jun2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 27954552
          Numbering:
            – Type: volume
              Value: 5
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: ARP Rheumatology
              Type: main
ResultId 1